<DOC>
	<DOCNO>NCT00420888</DOCNO>
	<brief_summary>The drug ABR-217620/naptumomab estafenatox fusion two protein , one recognize tumor cell one trigger attack tumor cell activate white blood cell belong body 's normal immune system . This result accumulation white blood cell cancer fight cancer . This study compare safety effectiveness ( assessed tumor status survival ) ABR-217620/naptumomab estafenatox give standard therapy IFN-alpha IFN-alpha alone patient advance renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>ABR-217620/Naptumomab Estafenatox With Interferon-alpha ( IFN-alpha ) Compared IFN-alpha Alone Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Histologically cytologically confirm RCC ( clear cell papillary type ) Metastatic inoperable locally advanced RCC Eligible therapy IFNalpha . Measurable disease define least 1 measurable lesion CT scan ( lesion diameter great equal 2.0 cm standard CT scanner great equal 1.0 cm spiral CT scanner ) Favorable moderate risk group prognosis MSKCC ( Motzer ) criterion ( score 02 ) Karnofsky performance status great equal 70 Age great equal 18 Life expectancy great 3 month Baseline blood count : Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Platelets great equal 100 x 10^9/L Haemoglobin great equal 100 g/L Baseline blood chemistry level : Creatinine le equal 1.5 x upper limit normal ( ULN ) Bilirubin le equal 2 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 2.5 x ULN . AST ALT allow less equal 5 x ULN patient liver metastasis . If fertile , patient use effective method contraception throughout study Willing able comply treatment followup visit examination Capable understanding parameter protocol able sign write consent form Pregnant breastfeed woman Serious uncontrolled medical disorder active infection ongoing resolve within 2 week first dose study drug investigator believe would impair patient 's ability receive study drug History malignancy within 5 year concurrent malignancy , except successfully treat nonmelanoma skin cancer , cervical cancer situ , ductal carcinoma situ lobular carcinoma situ breast may include History and/or sign parenchymal brain metastasis Significant cardiac disease include : history ( within 6 month ) current unstable angina pectoris , congestive heart failure ( NYHA stage IIIIV ) , myocardial infarction within 12 month , uncontrolled arterial hypertension . History stroke within 5 year and/or transient ischemic attack within 6 month . Acute illness evidence infection , include unexplained fever ( &gt; 100.5ºF 38.1ºC ) within 2 week start treatment Treatment biological response modifier within 3 week prior start treatment EndofStudy visit Treatment betablockers , include topical therapy glaucoma , within 5 day start treatment 4day ABR217620/naptumomab estafenatox treatment Treatment systemic corticosteroid within 2 week start treatment likely need treatment study Active autoimmune disease require therapy history systemic lupus erythematosus rheumatoid arthritis Known positive serology HIV Chronic hepatitis advance , decompensated hepatic disease cirrhosis liver history chronic virus hepatitis know virus carry ; patient recover Hepatitis A allow Treatment anticoagulant within 2 week start treatment , except use maintain patency central peripheral venous line Radiotherapy le 4 week start treatment Major surgery tumor embolization le 4 week start treatment Previous exposure murine monoclonal antibody know hypersensitivity murine proteins Currently renal dialysis treatment Known allergy hypersensitivity aminoglycosides kanamycin Previous systemic antitumor therapy RCC ( include immunotherapy IFNalpha IL2 chemotherapy ) except sunitinib oral antiangiogenic therapy Participation study investigational drug RCC within 6 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>